{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:39:10Z","timestamp":1789558750976,"version":"build-2803163510"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1016\/j.clinre.2010.10.003","type":"journal-article","created":{"date-parts":[[2011,2,8]],"date-time":"2011-02-08T01:37:09Z","timestamp":1297129029000},"page":"135-139","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Late anastomotic colonic dehiscence due to antiangiogenic treatment, a specific drug-class complication requiring specific treatment: An example of pazopanib complication"],"prefix":"10.1016","volume":"35","author":[{"given":"Clarisse","family":"Eveno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"le Maignan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Soyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Camus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Barranger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pocard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.clinre.2010.10.003_bib0005","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N Engl J Med"},{"issue":"6 Suppl.\u00a016","key":"10.1016\/j.clinre.2010.10.003_bib0010","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/sonc.2002.37263","article-title":"Role of angiogenesis in tumor growth and metastasis","volume":"29","author":"Folkman","year":"2002","journal-title":"Semin Oncol"},{"issue":"3","key":"10.1016\/j.clinre.2010.10.003_bib0015","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1158\/0008-5472.671.65.3","article-title":"Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies","volume":"65","author":"Gerber","year":"2005","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.clinre.2010.10.003_bib0020","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.2006.09.6305","article-title":"Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200","volume":"25","author":"Giantonio","year":"2007","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.clinre.2010.10.003_bib0025","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.clinre.2010.10.003_bib0030","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1200\/JCO.2005.10.017","article-title":"Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer","volume":"23","author":"Hurwitz","year":"2005","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clinre.2010.10.003_bib0035","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1200\/JCO.2003.10.066","article-title":"Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)\/leucovorin (LV) with FU\/LV alone in patients with metastatic colorectal cancer","volume":"21","author":"Kabbinavar","year":"2003","journal-title":"J Clin Oncol"},{"issue":"33","key":"10.1016\/j.clinre.2010.10.003_bib0040","doi-asserted-by":"crossref","first-page":"5326","DOI":"10.1200\/JCO.2008.16.3212","article-title":"Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE)","volume":"26","author":"Grothey","year":"2008","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clinre.2010.10.003_bib0045","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1093\/annonc\/mdp233","article-title":"Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study","volume":"20","author":"Van Cutsem","year":"2009","journal-title":"Ann Oncol"},{"issue":"26","key":"10.1016\/j.clinre.2010.10.003_bib0050","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N Engl J Med"},{"issue":"9605","key":"10.1016\/j.clinre.2010.10.003_bib0055","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.clinre.2010.10.003_bib0060","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.clinre.2010.10.003_bib0065","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1470-2045(09)70112-3","article-title":"Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis","volume":"10","author":"Hapani","year":"2009","journal-title":"Lancet Oncol"},{"issue":"33","key":"10.1016\/j.clinre.2010.10.003_bib0070","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","article-title":"Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer","volume":"25","author":"Cannistra","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinre.2010.10.003_bib0075","doi-asserted-by":"crossref","first-page":"18s","DOI":"10.1200\/jco.2010.28.18_suppl.lba1","article-title":"Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): a gynecologic oncology group study","volume":"28","author":"Burger","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clinre.2010.10.003_bib0080","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.ijrobp.2005.12.004","article-title":"Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases","volume":"64","author":"Lordick","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.clinre.2010.10.003_bib0085","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1136\/gut.2006.112524","article-title":"Bevacizumab and postponed suture leakages after surgery for ulcerative colitis and rectal cancer","volume":"56","author":"Adenis","year":"2007","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.clinre.2010.10.003_bib0090","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1007\/s10350-007-0231-8","article-title":"Delayed rectovaginal fistula: a potential complication of bevacizumab (avastin)","volume":"50","author":"Ley","year":"2007","journal-title":"Dis Colon Rectum"},{"issue":"3","key":"10.1016\/j.clinre.2010.10.003_bib0095","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/annonc\/mdm508","article-title":"Management of bevacizumab-associated bowel perforation: a case series and review of the literature","volume":"19","author":"Badgwell","year":"2008","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.clinre.2010.10.003_bib0100","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1080\/02841860601009471","article-title":"High incidence of fistula formation during bevacizumab treatment in rectal cancer patients","volume":"46","author":"Wolf","year":"2007","journal-title":"Acta Oncol"},{"issue":"2","key":"10.1016\/j.clinre.2010.10.003_bib0105","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/jso.20938","article-title":"\u201cSpontaneous\u201d delayed colon and rectal anastomotic complications associated with bevacizumab therapy","volume":"97","author":"August","year":"2008","journal-title":"J Surg Oncol"},{"issue":"4","key":"10.1016\/j.clinre.2010.10.003_bib0110","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00104-007-1339-z","article-title":"Ischemic anastomotic bowel perforation during treatment with bevacizumab 10 months after surgery","volume":"79","author":"Abbrederis","year":"2008","journal-title":"Der Chirurg"},{"issue":"4","key":"10.1016\/j.clinre.2010.10.003_bib0115","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1245\/s10434-008-0279-2","article-title":"Bevacizumab-related surgical site complication despite primary tumor resection in colorectal cancer patients","volume":"16","author":"Bege","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clinre.2010.10.003_bib0120","doi-asserted-by":"crossref","unstructured":"Deshaies I, Malka D, Soria JC, Massard C, Bahleda R, Elias D. Antiangiogenic agents and late anastomotic complications. J Surg Oncol 2010;101:180-183.","DOI":"10.1002\/jso.21447"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740110004298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740110004298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:09:49Z","timestamp":1761894589000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740110004298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["S2210740110004298"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2010.10.003","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2011,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Late anastomotic colonic dehiscence due to antiangiogenic treatment, a specific drug-class complication requiring specific treatment: An example of pazopanib complication","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2010.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}